| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Marion MacFarlane | |
| P433 | issue | 2-3 | |
| P921 | main subject | CD95 death-inducing signaling complex | Q14907122 |
| TRAIL death-inducing signaling complex | Q22327282 | ||
| apoptotic process | Q14599311 | ||
| death-inducing signaling complex | Q5247052 | ||
| P304 | page(s) | 89-97 | |
| P577 | publication date | 2003-04-01 | |
| P1433 | published in | Toxicology Letters | Q1796854 |
| P1476 | title | TRAIL-induced signalling and apoptosis | |
| P478 | volume | 139 |
| Q36216032 | ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer |
| Q33213461 | Absence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA Expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia |
| Q35002260 | Anti-tumor activity of a novel protein obtained from tartary buckwheat |
| Q40479030 | Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis. |
| Q37715814 | Apoptosis in leukemias: regulation and therapeutic targeting |
| Q37863133 | Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications |
| Q43273738 | Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis |
| Q33648419 | CHM-1, a new vascular targeting agent, induces apoptosis of human umbilical vein endothelial cells via p53-mediated death receptor 5 up-regulation. |
| Q36524672 | CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis |
| Q88634204 | Caspase selective reagents for diagnosing apoptotic mechanisms |
| Q37557634 | Cell death pathways--potential therapeutic targets |
| Q43172447 | Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. |
| Q54637021 | Characterization and expression analysis of TNF-related apoptosis inducing ligand (TRAIL) in grass carp Ctenopharyngodon idella. |
| Q45874985 | Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer |
| Q48884086 | Death receptor 5 and neuroproliferation |
| Q93035786 | Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation |
| Q37660616 | Death receptors: targets for cancer therapy |
| Q39625477 | Diarylheptanoid hirsutenone enhances apoptotic effect of TRAIL on epithelial ovarian carcinoma cell lines via activation of death receptor and mitochondrial pathway |
| Q40135330 | Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines |
| Q39374254 | Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells |
| Q39711397 | Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. |
| Q24793079 | Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts |
| Q33574958 | EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis |
| Q45947203 | Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. |
| Q33566824 | Enhancement of TRAIL-induced apoptosis by 5-fluorouracil requires activating Bax and p53 pathways in TRAIL-resistant lung cancers |
| Q35756884 | Epidermal growth factor and trail interactions in epithelial-derived cells. |
| Q40006446 | Erbin-regulated sensitivity of MCF-7 breast cancer cells to TRAIL via ErbB2/AKT/NF-kappaB pathway |
| Q35770122 | Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological |
| Q37096732 | FLIP as an anti-cancer therapeutic target |
| Q31120918 | Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5. |
| Q36287589 | Following the TRAIL from hepatitis C virus and alcohol to fatty liver |
| Q39177042 | Functional disruption of macrophage migration inhibitory factor (MIF) suppresses proliferation of human H460 lung cancer cells by caspase-dependent apoptosis |
| Q35613800 | Functions and mechanisms of action of the adenovirus E3 proteins |
| Q39426125 | Gomisin N enhances TRAIL-induced apoptosis via reactive oxygen species-mediated up-regulation of death receptors 4 and 5 |
| Q39545932 | Guanylate cyclase activator YC-1 enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells via activation of apoptosis-related proteins |
| Q24650617 | HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo |
| Q38338065 | Identification of a novel mechanism of NF-kappaB inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: induction of A20 and ABIN-2. |
| Q39454078 | Importin β1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells |
| Q64226381 | Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD |
| Q45886935 | In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL. |
| Q34803686 | In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas |
| Q81009343 | Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients |
| Q40286281 | Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. |
| Q33614335 | Interaction of dietary fatty acids with tumour necrosis factor family cytokines during colon inflammation and cancer |
| Q37745830 | Investigation on tissue specific effects of pro-apoptotic micro RNAs revealed miR-147b as a potential biomarker in ovarian cancer prognosis. |
| Q39181693 | Isolation, characterisation and reconstitution of cell death signalling complexes |
| Q38917597 | Loss of anchorage primarily induces non-apoptotic cell death in a human mammary epithelial cell line under atypical focal adhesion kinase signaling |
| Q39500273 | Luteolin induces apoptosis in multidrug resistant cancer cells without affecting the drug transporter function: involvement of cell line-specific apoptotic mechanisms |
| Q34208585 | Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor |
| Q37185605 | Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study |
| Q53214880 | Modulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors in a human osteoclast model in vitro. |
| Q36041769 | Neural precursor cells and their role in neuro-oncology |
| Q38907122 | Notch4 Signaling Confers Susceptibility to TRAIL-Induced Apoptosis in Breast Cancer Cells |
| Q47620185 | Novel targets for sensitizing breast cancer cells to TRAIL-induced apoptosis with siRNA delivery |
| Q48505113 | Ophiopogonin B sensitizes TRAIL-induced apoptosis through activation of autophagy flux and downregulates cellular FLICE-like inhibitory protein |
| Q42278494 | Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. |
| Q42849425 | Polyphenol acertannin prevents TRAIL-induced apoptosis in human keratinocytes by suppressing apoptosis-related protein activation |
| Q39498655 | Radicicol, an inhibitor of Hsp90, enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells by promoting activation of apoptosis-related proteins |
| Q46500389 | Recombinant TRAIL and TRAIL receptor analysis |
| Q61943533 | Relationship between tumour necrosis factor-related apoptosis inducing ligand (TRAIL) and vascular endothelial growth factor in human multiple myeloma patients |
| Q39924636 | Remote Limb Preconditioning Generates a Neuroprotective Effect by Modulating the Extrinsic Apoptotic Pathway and TRAIL-Receptors Expression |
| Q37992546 | Resistance to TRAIL and how to surmount it. |
| Q39721892 | Role of individual caspases induced by astrovirus on the processing of its structural protein and its release from the cell through a non-lytic mechanism. |
| Q28395683 | Salicylate-induced degeneration of cochlea spiral ganglion neurons-apoptosis signaling |
| Q33955186 | Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance |
| Q23924040 | Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells |
| Q45874298 | TRAIL and TRAIL receptors in patients with laryngeal cancer |
| Q37972139 | TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. |
| Q34564468 | TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. |
| Q64266102 | TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets? |
| Q38652074 | Targeting Apoptotic Activity Against Prostate Cancer Stem Cells |
| Q39103044 | The effect of sea anemone (H. magnifica) venom on two human breast cancer lines: death by apoptosis |
| Q40191072 | The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. |
| Q37374435 | The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. |
| Q40617085 | Thiothalidomides: Novel Isosteric Analogues of Thalidomide with Enhanced TNF-α Inhibitory Activity |
| Q38777719 | Thymoquinone inhibits growth of human medulloblastoma cells by inducing oxidative stress and caspase-dependent apoptosis while suppressing NF-κB signaling and IL-8 expression. |
| Q33302568 | Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists |
| Q35134937 | Tug of war between survival and death: exploring ATM function in cancer |
| Q36528568 | Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Gene Polymorphisms and Hepatitis B Virus Infection |
| Q42425074 | Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced mitochondrial pathway to apoptosis and caspase activation is potentiated by phospholipid scramblase-3. |
| Q34139591 | Tumor necrosis factor-related apoptosis-inducing ligand alters mitochondrial membrane lipids |
| Q44133700 | Tumor necrosis factor-related apoptosis-inducing ligand mediates the resolution of allergic airway inflammation induced by chronic allergen inhalation |
| Q40508879 | cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes |
| Q47805359 | miR-217-5p induces apoptosis by directly targeting PRKCI, BAG3, ITGAV and MAPK1 in colorectal cancer cells |
Search more.